Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-24T12:30:27.903Z Has data issue: false hasContentIssue false
  • English
  • Français

IBZM-SPECT imaging of dopamine D2 receptors with typical and atypical antipsychotics

Published online by Cambridge University Press:  16 April 2020

S Kasper ,
J Tauscher ,
E Küfferle ,
B Hesselmann ,
C Barnas  and
T Brücke
S Kasper
Affiliation:
Department of General Psychiatry, University of Vienna, Wahringer Gurtel 18-20, A-1090
J Tauscher
Affiliation:
Department of General Psychiatry, University of Vienna, Wahringer Gurtel 18-20, A-1090
E Küfferle
Affiliation:
Department of General Psychiatry, University of Vienna, Wahringer Gurtel 18-20, A-1090
B Hesselmann
Affiliation:
Department of General Psychiatry, University of Vienna, Wahringer Gurtel 18-20, A-1090
C Barnas
Affiliation:
Department of General Psychiatry, University of Vienna, Wahringer Gurtel 18-20, A-1090
T Brücke
Affiliation:
Department of General Neurology, University of Vienna, Vienna, Austria
Get access

Summary

Considerable progress has been achieved over the past 15 years in uncovering the biological basis of major psychiatric disorders. Since psychopharmacological treatment is thought tc act on the underlying biological basis of the disease, brain imaging techniques enable us to understand the mechanism of action of such compounds. One important tool used to determine patterns of brain dysfunction and how psychopharmacological agents such as antipsychotic compounds work is single-photon emission computerised tomography (SPECT). This technique allows determination of striatal D2 receptor occupancy rates, which are associated with the extrapyramidal side effects (EPS) of antipsychotic drugs. Studies have confirmed that atypical antipsychotic agents have lower occupancy rates than typical agents. No association has been found between D2 receptor occupancy rates n the striatum and antipsychotic efficacy, and it therefore appears that striatal D2 receptor occupancy rates are not necessary for the antipsychotic effect of such agents in schizophrenia. The availability of more refined radioligands will help us not only to understand the action of antipsychotics but also the pathophysiology of schizophrenia.

Keywords

antipsychoticsschizophreniadopaminereceptorsSPECT
Type
Research Article
Information
European Psychiatry , Volume 13 , Issue S1 , 1998 , pp. 9s - 14s
Copyright
Copyright © Elsevier, Pari 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Broich, K, Alavi, A, O'Brien, CP, Galloway, S, Mozley, DImaging of dopamine D2 receptors with [123I]-IBZM in normal controls with escalating doses of haloperidol [abstract] J Nucl Med 1992; 33: 898Google Scholar
Brücke, T, Podreka, L, Angelberger, P, Wenger, S, Topitz, A, Küfferle, B, et al.Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders J Cereb Blood Flow Metab 1991; 11: 220–228CrossRefGoogle ScholarPubMed
Brücke, T, Podreka, L, Wenger, S, Angelberger, P, Müller, C, Walter, H, et al.Dopamine receptor imaging with SPECT: A tool in extrapyramidal disorders and in vivo assay for the measurement of receptor blockade by neuroleptic treatment J Cereb Blood Flow Metab 11S21991 877Google Scholar
Brücke, T, Roth, J, Podreka, L, Strobl, R, Wenger, S, Asenbaum, SStriatal dopamine D2-receptor blockade by typical and atypical antipsychotics [letter] Lancet 1992; 339: 497CrossRefGoogle Scholar
Cambon, H, Baron, JC, Boulenger, JP, Loch, C, Zarifian, E, Maziere, BIn vivo assay for neuroleptic receptor binding in the striatum: positron tomography in humans Br J Psychiatry 1987; 151: 824–830CrossRefGoogle ScholarPubMed
Chouinard, G, Jones, B, Remington, G, Bloom, D, Addington, D, MacEwan, GW, et al.A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients J Clin Psychopharmacol 1311993 25–40CrossRefGoogle ScholarPubMed
Cordes, M, Henkes, H, Laudahn, D, Brau, H, Kramp, W, Girke, W, et al.Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease Eur J Radiol 1991; 12: 182–186CrossRefGoogle Scholar
Farde, L, Hall, H, Ehrin, E, Sedvall, GQuantitative analysis of D2 dopamine receptor binding in the living human brain by PET Science 1986; 231: 258–261CrossRefGoogle ScholarPubMed
Farde, L, Nordstrom, AL, Wiesel, FA, et al.Positron emission tomographic analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine Arch Gen Psychiatry 1992; 49: 538–544CrossRefGoogle ScholarPubMed
Gefvert, O, Lindstrom, LH, Langstrom, B, Bergstrom, M, Lundberg, T, Yates, RATime course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg ‘Seroquel’ Eur Neuropsychopharmacol 6suppl 31996 74CrossRefGoogle Scholar
Harasko-van der Meer, C, Brücke, T, Wenger, S, Fischer, P, Deecke, L, Podreka, ITwo cases of long-term dopamine D2 receptor blockade after depot neuroleptics J Neural Transm Gen Sect 1993; 94: 217–221CrossRefGoogle ScholarPubMed
Hirsch, SR, Link, CGG, Goldstein, JM, Arvanitis, LAICI 204,636: a new atypical antipsychotic drug Br J Psychiatry 168Suppl 291996 45–56CrossRefGoogle Scholar
Kane, JMSchizophrenia N Eng J Med 1996; 334: 34–41CrossRefGoogle ScholarPubMed
Karbe, H, Wienhard, K, Hamacher, K, Huber, M, Herholz, K, Coenen, HH, et al.Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol J Neural Transm Gen Sect 8631991 163–173CrossRefGoogle ScholarPubMed
Kasper, S(Potentielle) Antipsychotika mit neuartigen WirkmechanismenRiederer, , Laux, , Pöldinger, Neuro-Psychopharmaka, vol 4: Neuroleptika 1998 Springer-Verlag 489–499Google Scholar
Klemm, E, Grünwald, F, Kasper, S, Menzel, C, Broich, K, Danos, P, et al.[123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various antipsychotics Am J Psychiatry 1996; 153: 183–190Google Scholar
Küfferle, B, Brücke, T, Tauscher, J, Schratzberger-Topitz, A, Asenbaum, S, Podreka, I, Kasper, SIBZM SPECT and D2 dopamine receptor occupancy: different profiles with atypical antipsychotics Eur Neuropsychopharmacol 1995; 5: 337CrossRefGoogle Scholar
Küfferle, B, Brücke, T, Topitz-Schratzberger, A, Tauscher, J, Gössler, R, Vesely, C, et al.Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone Psychiatr Res-Neuroimaging 1996; 68: 23–30CrossRefGoogle ScholarPubMed
Kung, HF, Alavi, A, Chang, W, Kung, MP, Keyes, JW Jr, Velchik, MG, et al.In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans J Nucl Med 31 5 1990 573–579Google ScholarPubMed
Liebermann, JAUnderstanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development Br J Psychiatry 163 suppl 22 1994 7–18CrossRefGoogle Scholar
Meltzer, HYThe mechanism of action of novel antipsychotic drugs Schizophr Bull 1991; 17: 263–287CrossRefGoogle ScholarPubMed
Nyberg, S, Nakashima, Y, Nordström, AL, Halldin, C, Farde, LPositron emission tomography of in vivc binding characteristics of atypical antipsychotic drugs Review of D2 and 5HT2 receptor occupancy studies and clinical response Br J Psychiatry 168suppl 291996 40–44CrossRefGoogle Scholar
Pilowsky, LS, Costa, DC, Ell, PJ, Murray, Rm, Verhoeff, NPLG, Kerwin, RWClozapine, single photon emission tomography and the D2 dopamine receptor blockade hypothesis of schizophrenia Lancet 1992; 340: 199–202CrossRefGoogle ScholarPubMed
Pilowsky, LS, Busatto, GF, Taylor, M, Costa, DC, Sharma, T, Sigmundsson, T, et al.Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine — a 123I IBZM single photon emission tomography (SPET) study Psychopharmacology 1996; 124: 148–153CrossRefGoogle ScholarPubMed
Tauscher, J, Küfferle, B, Asenbaum, S, Brücke, T, Kasper, SPrevious treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine Psychopharmacology 1997; 133: 102–105CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.